Treatment options for

metastatic urothelial carcinoma:

eLearning activities

Publication date: 11 May 2022

Accreditation expiration date: 11 May 2023

Estimated time to complete: 15 minutes

Activity 2: Immunotherapy in advanced urothelial cancer: second-line and beyond

In this eLearning video module, Simon Chowdhury will explain the standard of care with immunotherapy in second- and subsequent treatment lines, reviewing potential factors that can influence treatment decisions in these settings.

Learning objectives

After completing this activity, you will be able to:

  • Discuss available immunotherapy options for second-line (and beyond) in patients with mUC
  • Interpret clinical data behind new immunotherapy options for patients whose disease have progressed after first-line therapy
  • Identify the best treatment strategy based on individual patient characteristics

Login to access this activity

  • This field is for validation purposes and should be left unchanged.

Module Content